Aldesleukin Terminated Phase 2 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00505635Biochemotherapy With Temozolomide for Metastatic Melanoma
NCT00706992Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients